Clemens Krepler at Wistar to Speak at Protein Kinases & Drug Design Conference Nov 8-9, 2012 Boston
Clemens Krepler, Staff Scientist of Meenhard Herlyn Laboratory, Tumor Microenvironment and Metastasis Program at Melanoma Research Center of The Wistar Institute Will Give a Presentation at the Protein Kinases and Drug Design Conference (Nov 8-9, 2012 in Boston, MA).
- San Diego, CA (1888PressRelease) October 09, 2012 - Clemens Krepler, Staff Scientist of Meenhard Herlyn Laboratory, Tumor Microenvironment and Metastasis Program at Melanoma Research Center of The Wistar Institute will give a presentation on "Unraveling the Potential of Novel Melanoma Therapies Through Advanced Preclinical Models" at the Protein Kinases and Drug Design conference taking place on Nov 8-9, 2012 in Boston, MA.
Recent clinical responses in melanoma with single agents are highly promising although patients ultimately relapse with drug-resistant tumors. Preclinical models must therefore be able to gauge novel therapies capable of achieving durable responses in patients. Three-dimensional (3D) culture systems have the potential to improve the in vivo pre-clinical identification of the most promising drug candidates and treatment strategies by mimicking the in vivo milieu. Patient derived xenograft (PDX) models are developed by collecting and implanting fresh biopsy tissue or fine needle aspirate (FNA) samples in NSG mice. The success rate of >90% is significantly higher than that of in vitro cell line generation. These advanced preclinical models provide a unique opportunity for further study of resistance mechanisms and effective drug combinations to ultimately improve accuracy in predicting clinical response.
Clemens Krepler, M.D. is staff scientist in Meenhard Herlyn's lab at the Wistar Institute, Philadelphia, PA. He is a specialist in dermatology, with a focus on dermato-oncology. In addition to his training as a general dermatologist, he has extensive experience in all aspects of melanoma management from primary diagnosis to surgical, adjuvant, and systemic therapy. He has been co-investigator on both phase 1/2 and phase 3 clinical trials and has published a number of high impact studies in the field of preclinical therapy of melanoma. In his present role, Dr. Krepler is conducting preclinical research in targeted therapy of melanoma using advanced models such as 3D spheroid cultures and patient derived xenografts. These projects are often in collaboration with external academic and industry partners and aim to maximize the benefit to melanoma patients by exploiting the wealth of new inhibitors currently in development.
GTC's Protein Kinases and Drug Design conference, one of two parallel tracks of the Cancer Summit - Novel Approaches to Drug Discovery on November 8-9 in Boston, MA, brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on drug design and development, selective and non-selective kinases inhibitors, hit and target identification, oncology kinases and inhibitors, and other kinases targets. Experts will also share their positive and negative experiences on how predictive preclinical models are with clinical efficacy and toxicology.
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam